Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

“Breakthrough” Therapies: Pharmacyclics Gains More Access, Certainty For Ibrutinib

Jun 10 2013

• By Derrick Gingery

Related Content

PDUFA Communications Hurt By Sequestration As Late-Stage Meetings Begin

Apr 08 2013

Breakthrough Therapies: FDA Not Writing A Scientific Guidance – Yet

Apr 29 2013

Should FDA Be Forced To Consider Development Time And Cost?

Nov 12 2012

Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model

Oct 01 2012

Industry Wants A Breakthrough Therapy, Even Without All The Standards

Oct 29 2012

FDA To Provide Expedited Approval Desktop Reference

Oct 29 2012

PDUFA V: Communications Liaisons Will Help Find Answers, Not Give Them

Oct 15 2012

What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers

May 13 2013

Related Companies

Pharmacyclics, Inc.

Johnson & Johnson

Additional Topics

United States Drug Approval Standards Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window